Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Inclusion Criteria: Participants must meet all of the following criteria: * Male or Female patients 18 years and older. * Patient with a diagnosis of chronic myelogenous leukemia in chronic phase * Within 6 months of initial diagnosis. * Received any treatment for CML for less than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide. Exclusion Criteria: * Late chronic phase, accelerated phase or blastic phase * Taking any other investigational agents within 28 days of starting the study * If sibling donors have been identified and where allogeneic bone marrow transplantation will be the first line treatment. * Another primary malignancy /cancer unless it is not considered clinically significant or does not require active intervention. * If patients have heart problems or complications * Pregnant or breast-feeding females * Severe and/or uncontrolled disease such as diabetes, chronic renal disease, etc. * Chronic liver disease (i.e., chronic active hepatitis, and cirrhosis). * Diagnosis of human immunodeficiency virus (HIV) infection. * Received any treatment for CML for longer than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide. * Patient previously received radiotherapy to greater than 25% of the bone marrow. * Patient had a major surgery within 4 weeks prior to study entry